Video

Evaluating risuteganib for dry eye disease treatment

Author(s):

David Hutton,Alex Delaney-Gesing

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.

Read more about the trial results here

See more ASCRS coverage

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
November 19th 2024

FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

New canalicular gel shows promise for dry eye treatment
November 13th 2024

New canalicular gel shows promise for dry eye treatment

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

Intense pulsed light for treatment of dry eye disease
October 31st 2024

Intense pulsed light for treatment of dry eye disease

© 2024 MJH Life Sciences

All rights reserved.